1. Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study. Issue 10 (20th August 2015) Authors: Miyagawa, J.; Odawara, M.; Takamura, T.; Iwamoto, N.; Takita, Y.; Imaoka, T. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Issue 3 (8th January 2016) Authors: Odawara, M.; Miyagawa, J.; Iwamoto, N.; Takita, Y.; Imaoka, T.; Takamura, T. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 3(2016) Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗